James Klinect serves as the founder and chief executive officer of The LOSA Collaborative in Austin, TX, a company that assists airlines with line operations safety audit (LOSA) procedures. Outside of his professional life, James Klinect supports numerous charities, including St. Jude Children’s Research Hospital.
St. Jude researchers say they have made an important discovery that will help determine acute megakaryoblastic leukemia (AMKL) patient groups that could be ideal for stem cell treatment. Recently published in the Nature Genetics journal, the study implemented genetic sequencing methods in an effort to analyze the specific ways AMKL presents itself in children who do not have Down syndrome.
New tests are currently being performed at St. Jude. Funding for the study was provided by organizations in Italy and the Netherlands as well as the St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project.
